Results 221 to 230 of about 340,254 (355)

Microvascular Health as a Key Determinant of Organismal Aging

open access: yesAdvanced Science, EarlyView.
This review spotlights the emerging field of vascular aging, providing a comprehensive and critical overview of the molecular processes and clinical manifestations of vascular dysfunction during aging. By combining basic angioscience concepts with a critical analysis of innovative pre‐clinical aging models and lifestyle interventions, it offers a ...
Mattia Cenciarini   +4 more
wiley   +1 more source

Polydopamine Nanodots Ameliorate Inflammatory Bowel Disease by Restoring Redox Homeostasis and Intestinal Microenvironment

open access: yesAdvanced Science, EarlyView.
A novel melanin‐based therapeutic composed of ultrasmall polydopamine nanodots is employed as an efficient oral formulation for the targeted treatment of inflammatory bowel disease. The potential therapeutic mechanism of polydopamine nanodots mainly involves the elimination of excessive oxidative stress, the reduction of ROS‐mediated proinflammatory ...
Zhen Ding   +11 more
wiley   +1 more source

The impact of storage time on coagulation factor activity in FFP. [PDF]

open access: yesFront Med (Lausanne)
Gao J   +11 more
europepmc   +1 more source

HLA alloimmunization and blood requirements in orthotopic liver transplantation. [PDF]

open access: yes, 1989
Duquesnoy, R   +5 more
core  

Procyanidin Capsules Combat ALF by Restoring Mitochondrial Homeostasis and Inhibiting Necroptosis via the PGAM5/DRP1/PINK1 Pathway

open access: yesAdvanced Science, EarlyView.
A biomimetic self‐assembly strategy, Procyanidin Capsules (PC‐Ca), has been developed, which has great stability, bioavailability, and liver‐targeting efficacy and modulates the KEAP1‐NRF2 axis to inhibit ROS formation and necroptosis, regulate mitochondrial homeostasis through the PGAM5/DRP1/PINK1 signaling pathway in thioacetamide (TAA)‐induced ALF ...
Qing Shi   +8 more
wiley   +1 more source

Hyaluronic Acid Hydrogel Implants for Sustained Release of Oxaliplatin and Resiquimod to Prevent Hepatocellular Carcinoma Recurrence Post‐Radiofrequency Ablation

open access: yesAdvanced Science, EarlyView.
Preparation of a biopolymer‐based immune implant (BI) for the sustained release of R848 and oxaliplatin (OXA), enabling immune activation and preventing recurrence after radiofrequency ablation (RFA) treatment in hepatocellular carcinoma (HCC). Abstract Hepatocellular carcinoma (HCC) remains a global challenge due to limited therapies and high ...
Yuezhan Shan   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy